 | • レポートコード：MRC2303M062 • 出版社/出版日：Mordor Intelligence / 2023年1月23日 • レポート形態：英文、PDF、114ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査資料によると、世界の骨髄異形成症候群（MDS）治療市場規模が、予測期間中（2022年〜2027年）に年平均成長率6.5%で拡大すると予測されています。本書は、骨髄異形成症候群（MDS）治療の世界市場にフォーカスし、最新動向と今後の市場性などをまとめており、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、治療別（化学療法、免疫治療、幹細胞移植、その他）分析、エンドユーザー別（病院、専門クリニック、その他）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来の動向などが掲載されています。また、AbbVie Inc.、Accord Healthcare、Bristol-Myers Squibb、Jazz Pharmaceuticals Inc.、Novartis AG、Lupin Pharmaceuticals、Otsuka America Pharmaceutical Inc.、Onconova Therapeutics、Takeda Pharmaceutical Company Limited、Astex Pharmaceuticals, Inc. 、Amgen Inc. 、Hikma Pharmaceuticals PLCなど、主要企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の骨髄異形成症候群（MDS）治療市場規模：治療別 - 化学療法の市場規模 - 免疫治療の市場規模 - 幹細胞移植の市場規模 - その他の市場規模 ・世界の骨髄異形成症候群（MDS）治療市場規模：エンドユーザー別 - 病院における市場規模 - 専門クリニックにおける市場規模 - その他における市場規模 ・世界の骨髄異形成症候群（MDS）治療市場規模：地域別 - 北米の骨髄異形成症候群（MDS）治療市場規模 アメリカの骨髄異形成症候群（MDS）治療市場規模 カナダの骨髄異形成症候群（MDS）治療市場規模 メキシコの骨髄異形成症候群（MDS）治療市場規模 … - ヨーロッパの骨髄異形成症候群（MDS）治療市場規模 イギリスの骨髄異形成症候群（MDS）治療市場規模 フランスの骨髄異形成症候群（MDS）治療市場規模 ドイツの骨髄異形成症候群（MDS）治療市場規模 … - アジア太平洋の骨髄異形成症候群（MDS）治療市場規模 中国の骨髄異形成症候群（MDS）治療市場規模 インドの骨髄異形成症候群（MDS）治療市場規模 日本の骨髄異形成症候群（MDS）治療市場規模 … - 南米/中東の骨髄異形成症候群（MDS）治療市場規模 ブラジルの骨髄異形成症候群（MDS）治療市場規模 アルゼンチンの骨髄異形成症候群（MDS）治療市場規模 南アフリカの骨髄異形成症候群（MDS）治療市場規模 … - その他地域の骨髄異形成症候群（MDS）治療市場規模 ・競争状況 ・市場機会・将来の動向 |
The myelodysplastic syndrome (MDS) treatment market is projected to register a CAGR of 6.5% during the forecast period, 2022-2027.
The COVID-19 (SARS-CoV-2) pandemic has had a variety of effects on cancer patients, including diagnostic and treatment delays, blood product scarcity, and, most importantly, increased morbidity and mortality from viral infection. For instance, as per the article titled “Myelodysplastic Syndromes (MDS) & COVID-19: Clinical Experience from the United States Epicenter of the Pandemic”, published in November 2020, records were reviewed of all patients seen in the MDS clinic of a large New York City tertiary academic medical center between March 12 and May 07, 2020. Among 85 patients seen in the clinic, 23 were found to have COVID-19. Nonetheless, such factors ultimately affected cancer care, causing the therapeutic pathway for MDS patients to be disrupted. This disruption to standard clinical care was exacerbated by the fear that COVID-19 would increase morbidity and mortality in immunocompromised MDS patients. There were fewer data available to guide treatment or protective recommendations in the early days of the pandemic, and advice was limited to expert opinion. Care interruptions had manifested as limited access to laboratory appointments for blood work assessment patients whose diseases required close observation and monitoring. Thus, the blood shortage had a significant impact on patients who required transfusional support, particularly those who lived in regions with few transfusion facilities. Patients undergoing chemotherapy also had to contend with shortened clinic or infusion center hours and inaccessible providers.
Furthermore, ongoing concern among chemotherapy patients that the resulting immunosuppression could make them more susceptible to COVID-19 infection and severe disease has shifted the balance between the risks and benefits of chemotherapy in many cases. As a result of the COVID-19 pandemic, the market studied has been impacted to a greater extent. However, with ongoing vaccinations and decreasing COVID-19 cases, the market studied is expected to regain its full potential during the forecast period.
The global market for myelodysplastic syndrome (MDS) treatment is expected to grow significantly over the coming years, owing to rising pipeline products and product approvals, as well as increased R&D investments in the development of novel drugs for MDS. For instance, Inqovi (decitabine and cedazuridine) tablets were approved by the United States Food and Drug Administration in July 2020 for the treatment of adult patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). This is a significant advancement in treatment options for patients with MDS, a type of blood cancer which previously required intravenous therapy at a healthcare facility.
Thus, the aforementioned factors are anticipated to contribute to the growth of the myelodysplastic syndrome (MDS) treatment market. However, side effects associated with the medications are likely to impede the market’s growth.
Myelodysplastic Syndrome (MDS) Treatment Market Trends
The Stem Cell Transplant Segment is Expected to Hold a Major Market Share in the Myelodysplastic Syndrome (MDS) Treatment Market
For patients with myelodysplastic syndromes, stem cell transplantation (SCT) offers a potentially beneficial therapy. There are two major types of SCT, one is an allogeneic stem cell transplant, and the other is an autologous stem cell transplant. In an allogeneic stem cell transplant, after the bone marrow is destroyed, the patient receives blood-forming stem cells from another person, the donor. This is the most common type of transplant for MDS. For instance, the study titled “Allogeneic stem cell transplantation may overcome the adverse impact of myelofibrosis on the prognosis of myelodysplastic syndrome” published on PubMed.gov in August 2021, concluded that patients with myelofibrosis (MF)-2/3 had a worse prognosis than those with myelofibrosis (MF)-0/1 in patients without allogeneic hematopoietic stem cell transplantation (allo-HSCT).
However, allogeneic SCTs can have serious, even life-threatening, side effects; thus, they are usually performed on younger, healthier patients. Patients in their 60s and even 70s have had successful transplants, but SCT is usually done with less intensive (reduced intensity) chemotherapy and/or radiation in older patients. Lower doses may not kill all bone marrow cells, but they are just enough to allow donor cells to take root and grow in the marrow. The lower doses also result in fewer side effects, making this type of transplant more tolerable for older patients. Even so, some serious side effects remain a possibility.
Additionally, patients receive their own stem cells after an autologous stem cell transplant (which were removed before treatment). As the patient’s bone marrow contains abnormal stem cells, this type of transplant is rarely used for MDS patients.
Thus, the abovementioned factors are expected to impact the segment’s growth over the analysis period.
North America is Expected to Hold a significant share in the market and is expected to do the Same in the Forecast Period.
North America dominates the global myelodysplastic syndrome (MDS) treatment market owing to the increase in the prevalence of myelodysplastic syndrome, early adoption of novel treatments, high R&D investments in the development of novel drugs, and the presence of sophisticated healthcare infrastructure. According to the American Society of Clinical Oncology (ASCO) 2022, MDS affects about 10,000 people in the United States each year. MDS is rare in people under the age of 50. However, people in their 70s are the most likely to develop it. The number of people diagnosed with MDS each year is expected to rise as the United States population ages.
Moreover, product approvals are increasing at a rapid pace, which is helping to drive market growth. Takeda Pharmaceutical Company Limited, for instance, announced in July 2020 that the FDA had granted Breakthrough Therapy Designation to its investigational drug pevonedistat for the treatment of patients with higher-risk myelodysplastic syndromes (HR-MDS). Pevonedistat, a first-in-class NEDD8-activating enzyme (NAE) inhibitor, could be the first new treatment for HR-MDS patients in over a decade, expanding treatment options previously limited to HMA monotherapy. Even with current treatment options, people with HR-MDS continue to have poor outcomes. Likewise, Novartis announced in November 2021 that the United States Food and Drug Administration (FDA) had granted fast-track designation for sabatolimab (MBG453) used in the treatment of adult patients with myelodysplastic syndromes (MDS) defined by an IPSS-R risk category of high or very high risk in combination with hypomethylating agents. Similarly, in September 2020, Gilead Sciences, Inc. announced that the United States Food and Drug Administration (FDA) had granted magrolimab, a first-in-class, investigational anti-CD47 monoclonal antibody for the treatment of newly diagnosed myelodysplastic syndrome, a Breakthrough Therapy designation.
Furthermore, rising patient awareness in the United States is expected to drive market growth over the forecast period. For instance, in September 2020, Jazz Pharmaceuticals plc announced the launch of Find the Right Fit, a patient education program in the United States developed in collaboration with the Myelodysplastic Syndromes (MDS) Foundation, Inc. and the Cancer Support Community to empower people with secondary acute myeloid leukemia (sAML) and MDS.
These factors together are likely to bolster the growth of the myelodysplastic syndrome (MDS) treatment market in the North American region.
Myelodysplastic Syndrome (MDS) Treatment Market Competitor Analysis
In the Myelodysplastic Syndrome (MDS) Treatment Market, major players are focused on expanding their business in different areas by adopting various market strategies, such as partnerships, collaborations, acquisitions, and mergers. Some of the major players operating in the market include AbbVie, Accord Healthcare, Bristol-Myers Squibb, Celgene Corporation, Takeda Pharmaceutical Company Limited, and Novartis AG, among others.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High R&D Investments on the Development of Novel Treatments for MDS
4.2.2 Strong Presence of Pipeline Drugs
4.3 Market Restraints
4.3.1 Side Effects Associated with the Medications
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Treatment Type
5.1.1 Chemotherapy
5.1.2 Immune Treatments
5.1.3 Stem Cell Transplant
5.1.4 Other Treatment Types
5.2 By End User
5.2.1 Hospitals
5.2.2 Specialty Clinics
5.2.3 Other End Users
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AbbVie Inc.
6.1.2 Accord Healthcare
6.1.3 Bristol-Myers Squibb
6.1.4 Jazz Pharmaceuticals Inc.
6.1.5 Novartis AG
6.1.6 Lupin Pharmaceuticals
6.1.7 Otsuka America Pharmaceutical Inc.
6.1.8 Onconova Therapeutics
6.1.9 Takeda Pharmaceutical Company Limited
6.1.10 Astex Pharmaceuticals, Inc.
6.1.11 Amgen Inc.
6.1.12 Hikma Pharmaceuticals PLC
7 MARKET OPPORTUNITIES AND FUTURE TRENDS